Lorlatinib

From Wikipedia, the free encyclopedia

Lorlatinib
Clinical data
Trade namesLorbrena, Lorviqua
Other namesPF-6463922
AHFS/Drugs.comMonograph
MedlinePlusa619005
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability81%
Protein binding66%
MetabolismMainly CYP3A4 and UGT1A4
Elimination half-life24 hrs (single dose)
Excretion48% urine (<1% unchanged), 41% faeces (9% unchanged)
Identifiers
  • (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.245.079 Edit this at Wikidata
Chemical and physical data
FormulaC21H19FN6O2
Molar mass406.421 g·mol−1
3D model (JSmol)
  • C[C@H]1Oc2cc(cnc2N)c3c(CN(C)C(=O)c4ccc(F)cc14)nn(C)c3C#N
  • InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
  • Key:IIXWYSCJSQVBQM-LLVKDONJSA-N

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer medication used for the treatment of non-small cell lung cancer.[4] It is an orally administered inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), two enzymes that play a role in the development of cancer.[6] It was developed by Pfizer.[7]

The most common adverse reactions include edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough.[7]

Lorlatinib was approved for medical use in the United States in November 2018,[8][9] and in the European Union in May 2019.[5]

Medical uses[edit]

Lorlatinib is indicated for the treatment of adults with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive.[4][5][6][7]

Contraindications[edit]

Lorlatinib must not be combined with strong inducers (i.e. activators) of the liver enzymes CYP3A4/5 if it can be avoided, as serious cases of liver toxicity have been observed under combination with the CYP3A4/5 inducer rifampicin.[4][10]

Side effects[edit]

The most common side effects in studies were high blood cholesterol (84% of patients), high blood triglycerides (67%), edema (55%), peripheral neuropathy (48%), cognitive effects (29%), fatigue (28%), weight gain (26%), and mood effects (23%). Serious side effects led to dose reduction in 23% of patients and to termination of lorlatinib treatment in 3% of patients.[4][10]

Interactions[edit]

Lorlatinib is metabolized by the enzymes CYP3A4/5. Therefore, CYP3A4/5 inducers such as rifampicin, carbamazepine or St John's wort decrease its concentrations in the blood plasma and can reduce its effectiveness. Additionally, the combination of lorlatinib with rifampicin showed liver toxicity in studies. Inhibitors of these enzymes such as ketoconazole or grapefruit juice increase lorlatinib plasma concentrations, leading to higher toxicity. Lorlatinib is also a (moderate) CYP3A4/5 inducer, so that drugs that are metabolized by these enzymes are broken down more quickly when combined with lorlatinib. Examples include midazolam and ciclosporin.[4][10]

Interactions via other enzymes have only been studied in vitro. According to these findings, lorlatinib may inhibit CYP2C9, UGT1A1 and several transport proteins, induce CYP2B6, and has probably no relevant effect on CYP1A2.[10]

Pharmacology[edit]

Mechanism of action[edit]

Further information: ALK inhibitor

Lorlatinib is a small molecule kinase inhibitor of ALK and ROS1 as well as a number of other kinases. It is active in vitro against many mutated forms of ALK.[4]

Pharmacokinetics[edit]

Lorlatinib is cleaved to the metabolite M8 (top left), which makes up 21% of the circulating substance, and an undetected metabolite (given in brackets). Other phase I metabolites are given in the bottom row. Most of these metabolites, as well as the original substance, undergo glucuronidation.[11]

Lorlatinib is taken by mouth and reaches highest blood plasma concentrations 1.2 hours after a single dose, or 2 hours after ingestion when taken regularly.[medical citation needed] Its absolute bioavailability is 80.8%.[medical citation needed] Intake with fatty food increases its availability by 5%, which is not considered clinically significant.[medical citation needed] When in the bloodstream, 66% of the substance are bound to plasma proteins.[4][10] Lorlatinib is able to cross the blood–brain barrier.[12]

Lorlatinib is inactivated by oxidation, mainly through CYP3A4, and by glucuronidation, mainly through UGT1A4.[medical citation needed] Other CYPs and UGTs play a minor role.[medical citation needed] Lorlatinib and its metabolites are excreted with a half-life of 23.6 hours after a single dose; 47.7% into the urine (of which less than 1% in unchanged form), and 40.9% into the faeces (9.1% unchanged).[10]

Chemistry[edit]

Lorlatinib is a white to off-white powder. It has high solubility in 0.1 M hydrochloric acid and very low solubility at a pH over 4.5.[11]

History[edit]

In November 2018, the US Food and Drug Administration (FDA) granted accelerated approval to lorlatinib for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.[8] Approval was based on a subgroup of 215 participants with ALK-positive metastatic NSCLC, previously treated with one or more ALK kinase inhibitors, enrolled in a non‑randomized, dose-ranging and activity-estimating, multi‑cohort, multicenter study (Study B7461001; NCT01970865).[8] The major efficacy measures were overall response rate (ORR) and intracranial ORR, according to RECIST 1.1, as assessed by an independent central review committee.[8]

In March 2021, the FDA granted regular approval to lorlatinib based on data from study B7461006 (NCT03052608), a randomized, multicenter, open-label, active-controlled trial conducted in 296 participants with ALK-positive metastatic non-small cell lung cancer who had not received prior systemic therapy for metastatic disease. Participants were required to have ALK-positive tumors detected by the VENTANA ALK (D5F3) CDx assay. Participants were randomized 1:1 to receive lorlatinib 100 mg orally once daily (n=149) or crizotinib 250 mg orally twice daily (n=147).

Society and culture[edit]

Legal status[edit]

In 2015, the FDA granted lorlatinib orphan drug status for the treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer.[13]

Lorlatinib was approved for medical use in the United States in November 2018,[8] and in the European Union in May 2019.[5][14][15]

Research[edit]

In June 2024, Pfizer announced positive longer-term follow-up results from the phase III CROWN study of lorlatinib in advanced non-small cell lung cancer showing that 60% of participants treated with lorlatinib were alive without disease progression after five years.[16][17][18]

References[edit]

  1. ^ a b "Lorviqua APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Archived from the original on 10 March 2024. Retrieved 10 March 2024.
  2. ^ "Lorbrena Product information". Health Canada. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  3. ^ "Summary Basis of Decision (SBD) for Lorbrena". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
  4. ^ a b c d e f g h "Lorbrena- lorlatinib tablet, film coated". DailyMed. 7 September 2023. Archived from the original on 7 May 2024. Retrieved 4 June 2024.
  5. ^ a b c d "Lorviqua EPAR". European Medicines Agency (EMA). 6 May 2019. Archived from the original on 14 November 2021. Retrieved 4 June 2024.
  6. ^ a b Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI (July 2020). "A user's guide to lorlatinib". Critical Reviews in Oncology/Hematology. 151: 102969. doi:10.1016/j.critrevonc.2020.102969. PMID 32416346.
  7. ^ a b c "FDA approves lorlatinib for metastatic ALK-positive NSCLC". U.S. Food and Drug Administration (FDA). 3 March 2021. Archived from the original on 11 September 2023. Retrieved 4 June 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ a b c d e "FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC". U.S. Food and Drug Administration (FDA). 14 December 2018. Archived from the original on 1 June 2024. Retrieved 4 June 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ^ "Drug Approval Package: Lorbrena (lorlatinib)". U.S. Food and Drug Administration (FDA). 10 December 2018. Archived from the original on 8 November 2022. Retrieved 4 June 2024.
  10. ^ a b c d e f "Lorviqua: EPAR – Product Information" (PDF). European Medicines Agency. 17 June 2019. Archived (PDF) from the original on 2 November 2021. Retrieved 26 September 2019.
  11. ^ a b "Lorviqua: EPAR – Public assessment report" (PDF). European Medicines Agency. 17 June 2019. Archived (PDF) from the original on 2 November 2021. Retrieved 26 September 2019.
  12. ^ "Lorlatinib". NCI Drug Dictionary. National Cancer Institute. 2 February 2011. Archived from the original on 15 October 2020. Retrieved 27 December 2020.
  13. ^ "Lorlatinib Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 29 March 2023. Retrieved 4 June 2024.
  14. ^ "European Commission Approves Lorviqua (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer, PM Pfizer, May 7, 2019". pfizer.com. Archived from the original on 15 May 2019. Retrieved 15 May 2019.
  15. ^ Syed YY (January 2019). "Lorlatinib: First Global Approval". Drugs. 79 (1): 93–98. doi:10.1007/s40265-018-1041-0. PMID 30604291. S2CID 57426966.
  16. ^ "Pfizer's Lorbrena CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression". Yahoo Finance. 31 May 2024. Archived from the original on 3 June 2024. Retrieved 3 June 2024.
  17. ^ "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC". ClinicalTrials.gov. 14 February 2024. Archived from the original on 1 June 2024. Retrieved 4 June 2024.
  18. ^ Solomon BJ, Liu G, Felip E, Mok TS, Soo RA, Mazieres J, et al. (May 2024). "Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology: JCO2400581. doi:10.1200/JCO.24.00581. PMID 38819031.

External links[edit]

  • Clinical trial number NCT01970865 for "A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations" at ClinicalTrials.gov
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lorlatinib&oldid=1227166398"